Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 2, 2002, Pages 143-150

  Tejada Berges, T ^a   Granai, C O ^a   Gordinier, M ^a   Gajewski, W ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Chemotherapy; Metastatic breast cancer; Pegylated liposomal doxorubicin; Recurrent ovarian cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; LIPOSOME; MACROGOL; MITOXANTRONE; NAVELBINE; PACLITAXEL; TOPOTECAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KAPOSI SARCOMA; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; OVARY CANCER; PROSTATE CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 0036081192     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.2.143     Document Type: Article

References (54)

1. Development of liposomal anthracyclines: From basics to clinical applications
2. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma
3. Doxorubicin in sterically stabilized liposomes
4. Stealth liposomal doxorubicin (Doxil) delivers more doxorubicin to AIDS-KS lesions than to normal skin
5. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
6. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy
7. Long-term stabilization patients with malignant glioma after treatment with liposomal doxorubicin
8. Multilevel therapeutic targeting by topoisomerase inhibitors
9. Epithelial ovarian cancer
10. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study of patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
11. Phase II study of intravenous topotecan as a 5-day infusion for refractory ovarian carcinoma
12. Topotecan in platinum and pactitaxel-resistant ovarian cancer
13. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma
14. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma
15. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
16. Risk factors for doxorubicin-induced congestive heart failure
17. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule
18. Impact of doxorubicin on survival in advanced ovarian cancer
19. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary Phase I studies
20. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: Analysis of toxicities and predictors of outcome
21. EORTC 10968: Phase I study of CAELYX™ at a six week interval in patients with metastatic breast cancer
22. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Caelyx/Doxil) in metastatic breast carcinoma
23. Phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen
24. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
25. Phase II trial of liposomal doxorubicin (Caelix) in relapses of cisplatin-refractory ovarian carcinoma
26. Phase II study of liposomal doxorubicin in advanced gynecological cancers
27. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
28. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancer and primary cancer of the peritoneum
29. A phase II Study of Doxil/Caelyx in Relapsed Ovarian Cancer (OC) Patients
30. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer
31. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter Phase II trial
32. The use of neoadjuvant Caelyx/Doxil in the treatment of stage III breast cancer
33. Randomised phase II trial of pegylated liposomal doxorubicin (CAELYX/DOXIL®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
34. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix
35. Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck
36. Doxil (Caelyx): An exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
37. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin
38. Cyotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
39. A Phase I study of liposomal doxorubicin (Caelyx/Doxil) with topotecan
40. Prolonged topotecan infusion combined with Caelyx/Doxil - A well tolerated regimen
41. Phase I study of Caelyx/Doxil plus escalating doses of Taxol in the treatment of patients with advanced breast or gynecologic malignancies
42. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer
43. Phase I study of Caelyx/Doxil and vinorelbine in metastatic breast cancer
44. Unexpected low efficacy of Caelyx and vinorelbine in metastatic breast cancer
45. Caelyx/Doxil® and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC): Interim results of ongoing pilot trial
46. Phase II study results on safety and tolerability of Caelyx (Doxil) in combination with paclitaxel in the treatment of metastatic breast cancer
47. Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HCl liposome injection (Caelyx/Doxil) plus paclitaxel (DT) in metastatic breast cancer
48. Recurrent epithelial ovarian carcinoma: A randomized phase iii study of pegylated doxorubicin versus topotecantecan
49. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
50. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS-Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
51. 2
52. Phase III study of TLCD-99 (liposome-encapsulated doxorubicin) vs. free doxorubicin in patients with metastatic breast cancer
53. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: The relation between pharmacokinetic property and toxicity
54. Use of chemotherapy plus a monoclonal antibody HER2 for metastatic breast cancer that overexpressed HER2